LIWANLI Innovation Co (3054) Fair Value & Analysis
Healthcare · TW · Market cap 4.5B TWD
Fair value as of: Jul 23, 2026
From 10 valuation models · updated 18 days ago
Share price −23.7% over the past month.
A solid business, but screening 62% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (38.64 TWD). The favourable scenario is already priced in.
- The model range is unusually wide (13.33 TWD to 38.64 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 18.50 TWD – 90.30 TWD · fair‑value band 13.33 TWD – 38.64 TWD · the 48.35 TWD price screens above the 18.17 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
LIWANLI Innovation Co (3054) currently trades at 48.35 TWD, while our model-based Fair Value estimate is 18.17 TWD, implying the stock looks roughly 62.4% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at 243M TWD. It earns a return on equity of 26.3%. The balance sheet holds a net cash position of 143M TWD. The stock trades on a trailing P/E of 35.1. Fundamentals as of Jul 23, 2026
Our scenario range runs from 13.33 TWD (bear case) to 38.64 TWD (bull case); at 48.35 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high and 120% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -62%, 3054 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Multiples (33.33 TWD) versus Dividend Discount (5.33 TWD). Highest evidence: Residual Income (76).
Notify me when 3054 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for males, females, the elderly, and children.
Full company description
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for males, females, the elderly, and children. Its products include black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, e-soothing powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, drops, and other products. The company was formerly known as Carry Technology International Co., Ltd. and changed its name to LIWANLI Innovation Co., Ltd. in 2015. LIWANLI Innovation Co., Ltd. was founded in 1980 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
LIWANLI Innovation Co reported revenue of 126M TWD in FY2025 versus 47.8M TWD in FY2021, a compound +27.3%/yr. Reported net income was 158M TWD in FY2025, compounding +36.5%/yr from FY2021.
3054 screens 62% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare LIWANLI Innovation Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is LIWANLI Innovation Co (3054) overvalued or undervalued?
What is the fair value of 3054?
What is the quality score of 3054?
What is the revenue of LIWANLI Innovation Co (3054)?
What is the net profit margin of 3054?
Does LIWANLI Innovation Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track LIWANLI Innovation Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.